Business Wire | Sep 24, 2020 03:35PM EDT

Company Profile for Axcella Health Inc.

Sep. 24, 2020

--(BUSINESS WIRE)--Sep. 24, 2020--Axcella (Nasdaq: AXLA) is a clinical-stage biotechnology company focused on leveraging endogenous metabolic modulators (EMMs) to pioneer a new approach for treating complex diseases and improving health. The company's product candidates are comprised of EMMs and their derivatives that are engineered in distinct combinations and ratios to simultaneously impact multiple biological pathways. Axcella's pipeline includes lead therapeutic candidates for non-alcoholic steatohepatitis (NASH) and the reduction in risk of overt hepatic encephalopathy (OHE) recurrence. Additional muscle- and blood-related programs are in earlier-stage development. For more information, please visit www.axcellahealth.com.

Company: Axcella Health Inc.



Headquarters Address: 840 Memorial Dr., Third Floor

CAMBRIDGE, MA 02139



Main Telephone: 857-320-2200



Website: www.axcellahealth.com



Ticker: AXLA(NASDAQ)



Type of Organization: Public



Industry: Biotechnology



Key Executives: CEO: Bill Hinshaw



Investor Relations

Contact: Jason Fredette

Phone: 7814240946

Email: jfredette@axcellahealth.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20200924005860/en/